| Margins | Consolidated EBITDA margin 4.87%, down 185 bps YoY. |
|---|---|
| Demand visibility | Bolivia 24-product tender won; direct Venezuela government tender secured. |
Growth
Consolidated revenue +53.4% YoY; EBITDA +11.2% to INR 299 Mn; owners' PAT +24.6% to INR 218 Mn.
Outlook
No numeric guidance. Targets 200+ B2C launches, Semaglutide commercialisation soon, new markets in Africa, Mexico and Kosovo.
Risks
Consolidated EBITDA margin down 185 bps to 4.87%; PAT margin down 138 bps; heavy LATAM tender and distributor dependence.
Investor Presentation filed with NSE, NSE: REMUS. Summary written with AI assistance from the document.
Remus Pharmaceuticals Ltd: key numbers
- Share price
- ₹815.00
- Market cap
- ₹960.4 Cr
- Revenue (annual)
- ₹853.6 Cr
- Net profit (annual)
- ₹36.99 Cr
- P/E (TTM)
- 26.0×Sector 41.3×
- Promoter holding
- 70.95%
- FII holding
- 5.10%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Remus Pharmaceuticals Ltd
All →Remus Pharmaceuticals Earnings Call Transcript: Key Takeaways
Remus delivered strong H1 growth led by international operations, though consolidated margins are skewed by a low-margin US distribution transaction.
Remus Pharmaceuticals Results Update
Remus Pharmaceuticals reported H1 FY27 results with standalone revenue of ₹62.08 Cr (up 32.51%) and consolidated revenue of ₹614.12 Cr (up 53.45%). The media release also highlights new tenders, approvals and portfolio expansion across international markets.
Remus Pharmaceuticals Dividend
Remus Pharmaceuticals has fixed 7 November 2026 as the record date for its 1st interim dividend for FY 2026-27, declared at today's board meeting. The filing does not state the per-share dividend amount.
Remus Pharmaceuticals H1 FY27 Results: Net Profit ₹24.7 Cr, Up 14.4% YoY
Remus Pharmaceuticals Ltd reported revenue from operations of ₹614.1 Cr (+53.4% YoY) and net profit of ₹24.7 Cr (+14.4% YoY) for H1 FY27.
- Key figure
- Net profit ₹24.7 Cr · +14.4% YoY
Remus Pharmaceuticals Other Announcement
Remus Pharmaceuticals filed its Reg 76 Reconciliation of Share Capital Audit Report for Q1 FY2027. It is a routine depository-compliance certificate with no transaction or business event.
Remus Pharmaceuticals Annual General Meeting
Remus Pharmaceuticals Limited shareholders approved the migration of equity shares from the NSE Emerge platform to the main boards of NSE and BSE.